Select a community
HIV
Find out more about the PatientsLikeMe
HIV Community
Home > Community Treatment Reports > Effexor XR (venlafaxine) Treatment Report
What is Effexor XR?

Effexor® XR is a brand name for the extended release preparation of the drug venlaflaxine, a prescription medicine used to treat depression, generalized anxiety disorder (also called "GAD"), and social anxiety disorder in adults. Read more...Click to read more below

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken # of patients Major Moderate Slight None Can’t tell # of patients evaluated by
Depression 14 2
Anxiety 2 1
Other 1 0

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
0 0%
Moderate
1 33%
Mild
1 33%
None
1 33%

Most commonly reported side effects

Drowsiness
2 67%
Panic attacks
1 33%
Suicidal thoughts
1 33%
  • Mild
  • Moderate
  • Severe

Dosages

  37.5 mg daily 75 mg daily 150 mg daily 300 mg daily
  2 Number of Patients: 2 3 Number of Patients: 3 6 Number of Patients: 6 4 Number of Patients: 4  

Stop Reasons

Why Patients Stopped Taking Effexor XR (multiple reasons could be selected)
Reason # Patients Percentage of patients
Side effects too severe
1 50% Side effects too severe: 50%
Other
1 50% Other: 50%

See all 2 patients who’ve stopped taking Effexor XR

Duration See details about how long patients take this treatment ▼

Currently Taking Effexor XR

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
1
0
3
3
2

Stopped Taking Effexor XR

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0
2

Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Always
3 100%
Usually
0 0%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
0 0%
A little
1 33%
Not at all
2 67%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
1 33%
< $25
0 0%

See more information, including instructions, precautions, side effects, and interactions.

Report created on November 21, 2009.